Idorsia: Aprocitentan Approval Is A Vital News [Seeking Alpha]
Viatris Inc. (VTRS)
Company Research
Source: Seeking Alpha
FDA approves Idorsia's Aprocitentan drug. There is a potential peak sales of over $2 billion. Despite positive developments, caution remains due to slow QUVIVIQ sales and the need for additional cost savings. Here at the Lab, following the exciting news on Idorsia ( OTC:IDRSF ), we are back to comment on the company equity story. Idorsia is a Switzerland-based biopharmaceutical player specializing in small molecule discovery. The company has a diverse pipeline and targets several diseases, including chronic insomnia, systemic lupus erythematosus, and resistant hypertension. Last year, our primary focus was on Idorsia's funding gap and QUVIVIQ sales pick-up. In detail, we published two pieces of research called Restructuring In Place and Dilution Risk Causes Downgrade To Hold . As a reminder, after the Q3 results, we analyzed Idorsia's potential funding options . The CEO mentioned that they have arrows on the bow , and even with limited options we recognized a few possibilities.
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Inflation Reduction Act: A Bullish Catalyst For Viatris Inc. [Seeking Alpha]Seeking Alpha
- Global Epilepsy Treatment Drugs Market Size To Exceed USD 12.1 Billion By 2033 | CAGR Of 4.36% [Yahoo! Finance]Yahoo! Finance
- Viatris Announces Product Donations To Direct Relief of More Than 7 Million Doses of Medicine To Support Access to Medicine and Healthcare [Yahoo! Finance]Yahoo! Finance
- Viatris to Report First Quarter 2024 Financial Results on May 9, 2024PR Newswire
- Viatris Appoints Corinne Le Goff as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 2/28/24 - Miss
VTRS
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/19/24 - Form 4
- 4/19/24 - Form 3
- VTRS's page on the SEC website